Trial Profile
A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine; Docetaxel; Gemcitabine
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms Keynote-122
- Sponsors Merck Sharp & Dohme Corp.
- 16 Dec 2022 Results of the final analysis, published in the Annals of Oncology
- 28 Oct 2022 Status changed from active, no longer recruiting to completed.
- 26 May 2022 Planned End Date changed from 26 May 2023 to 3 Oct 2022.